# Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas

> **NCT02739633** · PHASE2 · UNKNOWN · sponsor: **Samyang Biopharmaceuticals Corporation** · enrollment: 47 (estimated)

## Conditions studied

- Recurrent Adenocarcinoma of the Pancreas
- Metastatic Adenocarcinoma of the Pancreas

## Interventions

- **DRUG:** Genexol-PM
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02739633
- **Lead sponsor:** Samyang Biopharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2018-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02739633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02739633, "Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02739633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*